Who is sponsoring NCT03331432?

NCT03331432 is sponsored by University of Missouri-Columbia.

What drugs are being tested in NCT03331432?

Interventions in NCT03331432: Tauroursodeoxycholic acid, Placebo.

What condition does NCT03331432 study?

NCT03331432 studies Type 2 Diabetes Mellitus.

Is NCT03331432 still recruiting?

NCT03331432 is currently completed. Last updated 19 February 2018.

Last reviewed 2018-02-19 · How we verify

NCT03331432

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function

Completed NA Last updated 19 February 2018

What this trial tests

NA trial testing Tauroursodeoxycholic acid in Type 2 Diabetes Mellitus in 8 participants. Completed in 14 February 2018.

Timeline

28 October 2015

Primary endpoint
15 August 2017

14 February 2018

Quick facts

Lead sponsor	University of Missouri-Columbia
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	basic science
Enrollment	8
Start date	28 October 2015
Primary completion	15 August 2017
Estimated completion	14 February 2018
Sites	1 location across United States

Drugs / interventions tested

Tauroursodeoxycholic acid — full drug profile →
Placebo

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →

Sponsor

University of Missouri-Columbia

Who can join

Adults 20 to 65, any sex, with Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the present study is to determine if use of dietary supplement tauroursodeoxycholic acid enhances insulin-stimulated leg blood flow and glucose disposal.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Calcium Signaling in Liver Injury and Regeneration.
Oliva-Vilarnau N, Hankeova S, Vorrink SU, Mkrtchian S, et al · · 2018 · cited 61× · PMID 30023358 · DOI 10.3389/fmed.2018.00192
Tubulin-folding cofactor E deficiency promotes vascular dysfunction by increased endoplasmic reticulum stress.
Efentakis P, Molitor M, Kossmann S, Bochenek ML, et al · · 2022 · cited 12× · PMID 34132336 · DOI 10.1093/eurheartj/ehab222
The Critical Role of the Bile Acid Receptor TGR5 in Energy Homeostasis: Insights into Physiology and Therapeutic Potential.
Zangerolamo L, Carvalho M, Barbosa HCL. · · 2025 · cited 10× · PMID 40724796 · DOI 10.3390/ijms26146547
Endoplasmic reticulum stress in disease pathogenesis: its implications for therapy.
Wei S, Zhang N, Zhang H, Chen Z, et al · · 2026 · PMID 41986307 · DOI 10.1038/s41392-026-02600-z
Bile acids as therapeutic agents.
Vu B, Kawamoto R, Villalba-Davila P, Dong X, et al · · 2025 · PMID 41601986 · DOI 10.3389/fphar.2025.1732854

Verify or expand the search:

Other trials of Tauroursodeoxycholic acid

Trials testing the same drug.

NCT04727320 — The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis. · EARLY_PHASE1 · unknown
NCT03462940 — Effects of TUDCA on Endothelial Function in Type 2 DM · NA · terminated

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other University of Missouri-Columbia trials

Trials by the same sponsor.

NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
NCT07385105 — Evaluation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Individuals With Mild Traumatic Brain Injury (mTBI) · NA · not yet recruiting
NCT07067502 — Impact of Biphasic Cuirass Ventilation Compared to Non Invasive Ventilation in High Risk Extubations · NA · not yet recruiting
NCT07424079 — Metacognitive Strategy Training Intervention for Transition-Age Youth With Cerebral Palsy · NA · not yet recruiting
NCT07216196 — The Feasibility of a Remote Problem-Solving Intervention for Autistic Adolescents or Young Adults and a Caregiver · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03331432 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Missouri-Columbia
Last refreshed: 19 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03331432.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing